NYSEHealth CareBiotechnologySnapshot 2026-07-23
Reading DNA? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The current thesis state is mixed, with recent performance showing volatility and uncertainty in execution.
The market seems to have priced in a low level of execution quality, indicating a justified valuation that is cheap compared to peers. However, there is an expectations gap that suggests the market anticipates challenges ahead.
Fundamentals are likely to remain under pressure given the fragile earnings quality and elevated risk. The company has a near-term risk of missing earnings, especially as its industry peers have been struggling.
The thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX. Positive guidance from these companies could provide momentum, while negative guidance could lead to further challenges for DNA.
In the next 1 to 3 years, DNA's performance will depend heavily on management's ability to navigate cash burn and execute on strategic priorities. Not investment advice.
The most important moves since the prior daily snapshot.
No, our read on the company is unchanged. There are no new strengths or weaknesses noted. Recent financial performance remains steady but below its industry peers. Management is still behind on a stated commitment, which is a concern.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: The recent earnings miss raises concerns about cash management. This could impact future operations.
Confirms:Cash burn is reported much higher than $150M in the next quarters.
Disproves:Cash burn reported within the $125M to $150M range.
Why it matters: Earnings results will provide insight into Ginkgo's financial health and growth prospects. A miss could signal ongoing issues.
Confirms one read:The earnings report shows revenue growth and better financial numbers.
Confirms the other:Earnings report shows continued losses or revenue decline.
Why it matters: A revenue drop below $20 million would show ongoing struggles after a 49% decline in Q1.
Confirms:Q2 2026 revenue reported below $20 million.
Disproves:Q2 2026 revenue reported above $20 million.
Why it matters: The earnings report will show if the company can improve its financial situation. Investors will look for signs of profitability.
Confirms one read:The earnings report shows smaller losses. It also shows a way to make money.
Confirms the other:The earnings report shows bigger losses. There is no clear way to make money.
Why it matters: If revenue growth picks up, it could help Ginkgo Bioworks. The sector's health affects its performance.
Confirms:Sector revenue growth moves back toward 10% or higher.
Disproves:Sector revenue growth keeps slowing down. It is now below 10%.
Why it matters: Achieving this revenue target is critical for Ginkgo's growth narrative. It shows the success of their Biosecurity segment.
Confirms:Biosecurity revenue reports show at least $40M for 2025.
Disproves:Biosecurity revenue falls short of $40M in 2025.
Why it matters: Finishing the deal would show a new direction and possible money growth for Ginkgo.
Confirms:An official notice that the Tower Biosecurity deal is done.
Disproves:A notice about delays or stopping the deal.
Why it matters: If cash burn goes over $150 million, it raises worries about money management.
Confirms:Reported cash burn for 2026 exceeds $(150) million.
Disproves:Reported cash burn for 2026 is $(150) million or less.
